Is axitinib/axitinib a targeted drug? Analysis of mechanism of action and clinical indications

Axitinib/Axitinib is a targeted drug and a multi-target tyrosine kinase inhibitor. Its mechanism of action mainly exerts anti-tumor effects by inhibiting tyrosine kinase receptors related to tumor angiogenesis. Axitinib can target and inhibit multiple vascular endothelial growth factor receptors (VEGFR) and other molecules related to tumor growth and metastasis, such as PDGFR (platelet-derived growth factor receptor) and c-KIT. Through this mechanism, axitinib reduces the blood supply to tumor cells, thereby inhibiting tumor growth and spread.

Clinically, axitinib is mainly used to treat advanced renal cell carcinoma (RCC), especially when first-line treatment fails or is resistant, and is usually used as a second-line treatment. Axitinib is an oral drug that slows tumor progression by inhibiting tumor angiogenesis and reducing the blood supply required for tumor growth. The clinical application of axitinib also includes the treatment of some other malignant tumors. Although it is mainly used in renal cell carcinoma, its potential in the treatment of other tumors is under further study.

The therapeutic mechanism of axitinib is particularly important for patients with advanced renal cell carcinoma. Because renal cell carcinoma is a highly malignant tumor, and its treatment often requires the combination of targeted therapy and immunotherapy, axitinib, as an effective targeted drug, can prolong the progression-free survival (PFS) and improve the quality of life of patients. In clinical studies, axitinib has shown good efficacy in combination with other targeted drugs, especially in patients who have previously received poor response to other treatment options (such as sunitinib, sorafenib).

In summary, axitinib, as a targeted drug, has demonstrated significant efficacy in the treatment of advanced renal cell carcinoma by virtue of its inhibitory effect on multiple angiogenesis-related molecules.

Reference materials:https://en.wikipedia.org/wiki/Axitinib